GBC’s Specialty Oncology Injectable Generic Drugs Authorized Europe, Commercially Supply will Credit Increased Revenue in 2023-24
Today, GBC, sterile injection drug development and CDMO organization, announced that it has successfully licensed several self-developed specialty oncology lyophilized injectable generic drugs to well-known Europe pharmaceutical Companies and completed the contracts. This exclusive Europe authorization includes MA application and distribution of medicinal products. GBC will exclusively supply the customers’ demand for injection drugs in Europe and will share the benefit. It is expected that customers will be granted MA next year and GBC will commercially supply and credit increased revenue.